Home/Filings/4/0001493152-21-004623
4//SEC Filing

Glynn Craig 4

Accession 0001493152-21-004623

CIK 0001661053other

Filed

Feb 22, 7:00 PM ET

Accepted

Feb 23, 5:21 PM ET

Size

8.0 KB

Accession

0001493152-21-004623

Insider Transaction Report

Form 4
Period: 2020-07-18
Glynn Craig
Chief Financial Officer
Transactions
  • Award

    Stock Option

    2020-07-18+4,0004,000 total
    Exercise: $10.00Exp: 2030-07-18Common Stock (4,000 underlying)
  • Award

    Stock Option

    2021-02-18+324,000324 total
    Exercise: $8.20Exp: 2031-02-18Common Stock (324 underlying)
Footnotes (3)
  • [F1]The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan").
  • [F2]The stock option vests in equal quarterly installments over a three year period commencing October 18, 2020.
  • [F3]The stock options vest in equal quarterly installments over a three year period, however the stock options may only become exercisable following receipt by the registrant of stockholder approval to increase the size of the Plan sufficiently to permit the exercise in full of such stock options under the Plan. If the registrant's stockholders do not approve an increase in the size of the Plan, the options will be void.

Documents

1 file

Issuer

Hancock Jaffe Laboratories, Inc.

CIK 0001661053

Entity typeother

Related Parties

1
  • filerCIK 0001809590

Filing Metadata

Form type
4
Filed
Feb 22, 7:00 PM ET
Accepted
Feb 23, 5:21 PM ET
Size
8.0 KB